OSE Immunotherapeutics Announces Issuance of a European Patent Protecting FR104, CD28-Antagonist Immunotherapy

The patent covers therapeutic applications of FR104 in Europe in autoimmune diseases,
chronic inflammatory diseases and graft applications through 2031…